Lucid Diagnostics Inc. intends to offer shares of common stock through an underwritten public offering.
The offering includes granting the underwriters a 30-day option to purchase additional shares of common stock to support working capital and general corporate purposes.
The completion of the offering is subject to market conditions with uncertainties regarding timing, size, and terms.
Intended Public Offering
Lucid Diagnostics Inc. plans to offer shares of common stock through an underwritten public offering to raise funds for working capital and general corporate purposes.
Underwriters
Canaccord Genuity LLC and BTIG, LLC are the joint bookrunners, while Maxim Group LLC is the co-manager of the offering.
Registration Statement
The offering is made pursuant to a shelf registration statement on Form S-3 (File No. 333-268560) declared effective by the SEC on December 6, 2022.
- The offering aims to support Lucid Diagnostics in funding its operations and advancing its diagnostic tools designed for early detection of esophageal precancer.
- The involvement of reputable underwriters signifies market confidence in Lucid's offerings and potential growth opportunities.
This press release highlights Lucid Diagnostics Inc.'s strategic move to raise capital through a public offering, showcasing its commitment to advancing cancer prevention diagnostics.